Background: Most HIV-infected patients attending a consultation-liaison psychiatry service show symptoms of anxiety and depression. The present study sought to evaluate the immediate and long-term efficacy of a structured cognitive-behavioural group therapy reducing anxiety and depression in HIV-infected patients referred to a consultation-liaison psychiatry department, and to identify baseline variables predictive of greater improvement. Methods: Repeated-measures ANOVA was used to analyse changes in the Beck Depression Inventory (BDI) and the state subscale of the State/Trait Anxiety Inventory (STAI) administered to 39 participants at 4 time points: T1 (1 month before beginning the therapy), T2 (during the first session), T3 (during the last session) and T4 (3 months after the last session). The therapy consisted of 16 weekly 2-hour sessions following a structured time-limited cognitive-behavioural group psychotherapy programme. Results: During the intervention time (between T2 and T3) an improvement was observed in depression and anxiety, which persisted after the 3-month follow-up period (between T3 and T4). No changes were observed during baseline (between T1 and T2). Patients with higher levels of anxiety at baseline showed greater improvement in STAI state subscale scores. Transmission of HIV infection through intravenous drug use was associated with less improvement on the BDI. Conclusions: This is the first report of an ongoing study which suggests long-lasting efficacy of a structured cognitive-behavioural group psychotherapy programme in a heterogeneous sample of HIV-1-infected patients referred to a consultation-liaison psychiatry unit.

Keywords:
Cognitive-behavioural psychotherapy, Group psychotherapy, HIV-1 infection, Consultation-liaison psychiatry, Depression, Anxiety
1.
McDaniel JS, Fowlie E, Summerville MB, Farber EW, Cohen-Cole SA: An assessment of rates of psychiatric morbidity and functioning in HIV disease. Gen Hosp Psychiatry 1995;17:346–352.
2.
Judd FK, Cockram A, Mijch A, McKenzie D: Liaison psychiatry in an HIV/AIDS unit. Aust NZ J Psychiatry 1997;31:391–397.
3.
Wolcott D, Fawzy F, Pasnau R: Acquired immune deficiency syndrome (AIDS) and consultation-liaison psychiatry. Gen Hosp Psychiatry 1985;7:280–292.
4.
Wagner GJ, Rabkin JG, Rabkin R: A comparative analysis of standard and alternative antidepressants in the treatment of human immunodeficiency virus patients. Compr Psychiatry 1996;37:402–408.
5.
Targ EF, Karasic DH, Diefenbach PN, Anderson DA, Bystristsky, Fawzy FI: Structured group therapy and fluoxetine to treat depression in HIV-positive persons. Psychosomatics 1994;35:132–137.
6.
Kelly JA, Murphy DA, Bahr GR, Kalichman SC, Morgan MG, Stevenson LY, Koob JJ, Brasfield TL, Bernstein BM: Outcome of cognitive-behavioural and support group brief therapies for depressed, HIV-infected persons. Am J Psychiatry 1993;150:1679–1686.
7.
Church J: The application of cognitive-behavioural therapy for depression to people with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS). Psychooncology 1998;7:78–88.
8.
Kelly JA: Group psychotherapy for persons with HIV and AIDS-related illnesses. Int J Group Psychother 1998;48:143–162.
9.
Beresnevaite M: Exploring the benefits of group psychotherapy in reducing alexithymia in coronary heart disease patients: A preliminary study. Psychother Psychosom 2000;69:117–122.
10.
Lee MR, Cohen L, Hadley SW, Goodwin FK: Cognitive-behavioural group therapy with medication for depressed gay men with AIDS or symptomatic HIV infection. Psychiatr Serv 1999;50:948–952.
11.
Selwyn PA, Arnold R: From fate to tragedy: The changing meanings of life, death and AIDS. Ann Intern Med 1998;129:899–902.
12.
Riemer D, Bock J, Escobar LC, Hautzinger M: Gruppen-Psychotherapie für Menschen mit HIV/AIDS. Psychotherapeut 1998;43:198–204.
13.
Beck AT, Rush AJ, Shaw BF, Emery G: Cognitive Therapy of Depression. New York, Guilford, 1979.
14.
Emmelkamp PMG: Psychosocial factors in HIV-AIDS. Psychother Psychosom 1996;65:225–228.
15.
Chung JY, Magraw MM: A group approach to psychosocial issues faced by HIV-positive women. Hosp Community 1992;43:891–894.
16.
Spitzer RL, Williams JBW: Structured Clinical Interview for DSM-III-R, Patient Version with Psychotic Symptoms. New York, New York Psychiatric Institute, 1987.
17.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–571.
18.
Spielberger CD, Gorsuch RL, Lushene RE: STAI – Manual for the State-Trait Anxiety Inventory (Self-Evaluation Questionnaire). Palo Alto, Consulting Psychologists Press, 1970.
19.
Karnofsky DA: The Clinical Evaluation of Chemotherapeutic Agents in Cancer. New York, Columbia University Press, 1949, pp 191–205.
20.
Markowitz JC, Kocsis JH, Fishman B, Spielman LA, Jacobsberg LB, Frances AJ, Klerman GL, Perry SW: Treatment of depressive symptoms in human immunodeficiency virus-positive patients. Arch Gen Psychiatry 1998;55:452–457.
21.
Goodkin K, Blaney NT, Feaster DJ, Baldewicz T, Burkhalter JE, Leeds B: A randomised controlled clinical trial of a bereavement support group intervention in human immunodeficiency virus type 1-seropositive and -seronegative homosexual men. Arch Gen Psychiatry 1999;56:52–59.
22.
Mulder CL, Emmelkamp PMG, Antoni MH, Mulder JW, Sandford TGM, de Vries MJ: Cognitive-behavioural and experimental group psychotherapy for infected homosexual men: A comparative study. Psychosom Med 1994;56:423–431.
23.
Mulder CL, Antoni MH, Emmelkamp PMG, Veugelers PJ, Sandford TGM, van de Vijer FAJR, de Vries MJ: Psychosocial group intervention and the rate of decline of immunological parameters in asymptomatic HIV-infected homosexual men. Psychother Psychosom 1995;63:185–192.
24.
Grassi L, Righi R, Makoui S, Sighinolfi L, Ferri S, Ghinelli F: Illness behaviour, emotional stress and psychological factors among asymptomatic HIV-infected patients. Psychother Psychosom 1999;68:31–38.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.